Med24
metabolic-therapy 30. 10. 2026 • 2 min read • Metabolism: clinical and experimental (PubMed)

The metabolic-brain axis: GLP-1 signaling, insulin resistance, and obesity pharmacotherapy in neurodegeneration.

The intersection of metabolic disease and neurodegeneration represents one of the most consequential frontiers in translational neuroscience. Converging epidemiological, mechanistic, and pharmacological evidence supports a bidirectional metabolic-brain axis in which systemic insulin resistance, obesity, and chronic...

Knowledge and self-reported practice of laboratory biosafety among medical laboratory professionals in selected public and private hospitals in Mogadishu, Somalia: a cross-sectional study

The connection between metabolic disorders and neurodegeneration is a significant area of research. Evidence suggests a reciprocal relationship where insulin resistance, obesity, and chronic metabolic inflammation are linked to changes in brain function, including neuronal survival, synaptic plasticity, and neuroimmune processes. **GLP-1** receptor agonists, initially developed for diabetes and weight management, are being explored as potential treatments for neurodegenerative conditions like Alzheimer’s and Parkinson’s disease. These agonists may influence neuronal activity through **PKA** activation, reduce inflammation via **NLRP3** suppression, promote mitochondrial function, and restore **AQP4** localization for enhanced waste clearance. Support for these mechanisms comes primarily from preclinical models and indirect human data.

Key Clinical Findings

Currently, direct human evidence for these central nervous system mechanisms is limited. Two large clinical trials, **EVOKE/EVOKE+** in Alzheimer’s disease and **Exenatide-PD3** in Parkinson’s disease, did not show a statistically significant benefit on their primary clinical endpoints. These trials, despite prior biomarker and epidemiological findings, failed to confirm the anticipated therapeutic effects.

Sponsored content

Synthesis and Future Directions

The review synthesizes current understanding of brain insulin signaling, central **GLP-1** biology, obesity-related neuroinflammation, and the translational evidence surrounding metabolic therapies for neurodegenerative diseases. It highlights the need for further investigation into **CNS** target engagement, optimal dosing strategies, and the potential for achieving disease-modifying efficacy with **GLP-1** receptor agonists.

Original Scientific Source
Metabolism: clinical and experimental (PubMed)
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Nanotechnology-Driven 18F-FDG Imaging to Understand the Change in Insulin Sensitivity: Current Evidence, Methodological Gaps, and Translational Challenges.
metabolic-therapy

Nanotechnology-Driven 18F-FDG Imaging to Understand the Change in Insulin Sensitivity: Current Evidence, Methodological Gaps, and Translational Challenges.

Insulin resistance is an important metabolic derangement contributing to the pathogenesis of type 2 diabetes, obesity, metabolic syndrome, and other chronic diseases, underlining the requirement for techniques that enable in vivo analysis of tissue-specific glucose metabolism. 18F-fluorodeoxyglucose positron emission...

10. 11. 2026 Read article →
Cardiometabolic Abnormalities among Normal-Weight Adults: Prevalence and Associated Sociodemographic and Lifestyle Factors in a Large Spanish Cohort.
metabolic-therapy

Cardiometabolic Abnormalities among Normal-Weight Adults: Prevalence and Associated Sociodemographic and Lifestyle Factors in a Large Spanish Cohort.

BACKGROUND: Although body mass index (BMI) is widely used to assess obesity-related health risks, it may fail to detect individuals with normal weight who present with significant cardiometabolic abnormalities. This phenotype, often overlooked in clinical practice, is associated with increased risk of cardiovascular...

30. 10. 2026 Read article →
Advertisement